Asceneuron

8 articles about Asceneuron

• Asceneuron Welcomes Barbara Angehrn Pavik as New CEO as It Gears Up for Next Phase of Growth

  10/6/2023

  Asceneuron SA announced the appointment of Barbara Angehrn Pavik as the new Chief Executive Officer, as part of a leadership transition poised to propel the company into its next phase of growth, with two compounds in clinical development.

• Ferrer Acquires Worldwide Rights to ASN90, an O-GlcNAcase Inhibitor From Asceneuron, Exclusively to Treat Progressive Supranuclear Palsy (PSP)

  2/22/2023

  Spanish pharmaceutical company Ferrer and Swiss clinical stage biotechnology company Asceneuron announce the signing of a licensing agreement in which Ferrer obtains the exclusive worldwide rights to develop and commercialize ASN90 in progressive supranuclear palsy, an orphan, tau-related disease with a high unmet medical need.

• Asceneuron appoints experienced CNS clinician Dr Eric Yuen to the Board of Directors

  5/20/2019

  Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau for the treatment of neurodegenerative diseases, today announces the appointment of Dr Eric Yuen to its Board of Directors.

• Asceneuron appoints Peter Van Vlasselaer as Chairman

  1/17/2019

  Asceneuron, an emerging leader in the development of orally bioavailable modulators of tau pathology for the treatment of neurodegenerative diseases, today announces the appointment of Peter Van Vlasselaer as Chair of the Board of Directors.

• Asceneuron initiates neuroimaging trial for tau modifier ASN120290

  11/20/2018

  Asceneuron SA announced today it has commenced a new clinical trial of its lead asset, ASN120290.

• Asceneuron Receives Regulatory Approval For Phase I Healthy Volunteer Study Of Oral Tau Inhibitor

  4/6/2017

• Asceneuron Appoints J. Michael Ryan, M.D. As Chief Medical Officer

  12/6/2016

• Asceneuron Receives Grant From The Michael J. Fox Foundation For Parkinson's Research

  10/6/2016